Annexin A1 and the regulation of innate and adaptive immunity.
Annexin A1 and the regulation of innate and adaptive immunity.
复制标题
Annexin A1以及对先天和适应性免疫的调节。
DOI：
10.3389/fimmu.2012.00354
复制
发表时间：
2012
影响因子：
7.3
通讯作者：
Hickey MJ
中科院分区：
文献类型：
--
作者：
Gavins FN;Hickey MJ
炎症是身体抵御有害刺激和病原体的方式。在正常情况下，身体能够消除侮辱，随后促进炎症的消退和受损组织的修复。动态平衡的概念不仅要求在促炎介质和促消解/抗炎介质之间取得微妙的平衡，而且还要求这种平衡以特定的时间和空间方式发生。该综述考察了Annexin A1，一种抗炎蛋白，当用作外源性治疗时，已被证明在各种实验模型中非常有效地限制炎症，包括心肌缺血/再灌注损伤、关节炎、中风、多发性硬化症和脓毒症。值得注意的是，这种糖皮质激素诱导蛋白与另一种抗炎介质脂氧素A4一起，开始帮助解释和塑造我们对炎症消退阶段的理解。在这样做的过程中，这些分子正在为创新的药物发现开辟道路，这是基于内源性促进分解途径的刺激。
Inflammation is the body’s way of defending itself against noxious stimuli and pathogens. Under normal circumstances, the body is able to eliminate the insult and subsequently promote the resolution of inflammation and the repair of damaged tissues. The concept of homeostasis is one that not only requires a fine balance between both pro-inflammatory mediators and pro-resolving/anti-inflammatory mediators, but also that this balance occurs in a time and space-specific manner. This review examines annexin A1, an anti-inflammatory protein that, when used as an exogenous therapeutic, has been shown to be very effective in limiting inflammation in a diverse range of experimental models, including myocardial ischemia/reperfusion injury, arthritis, stroke, multiple sclerosis, and sepsis. Notably, this glucocorticoid-inducible protein, along with another anti-inflammatory mediator, lipoxin A4, is starting to help explain and shape our understanding of the resolution phase of inflammation. In so doing, these molecules are carving the way for innovative drug discovery, based on the stimulation of endogenous pro-resolving pathways.